A. Meyer, B. Lannes, J. Goetz, A. Echaniz-laguna, D. Lipsker et al., Inflammatory myopathies: A new landscape, Joint Bone Spine. janv, vol.85, issue.1, pp.23-33, 2018.

H. , Myositis mimics: how to recognize them. Current Opinion in Rheumatology, vol.26, pp.663-70, 2014.

D. Dimitri, Myopathies inflammatoires : diagnostic et classifications, La Presse Médicale. juill, vol.38, issue.7-8, pp.1141-63, 2009.

A. Meyer, N. Meyer, M. Schaeffer, J. Gottenberg, B. Geny et al., Incidence and prevalence of inflammatory myopathies: a systematic review, Rheumatology. janv, vol.54, issue.1, pp.50-63, 2015.

M. C. Dalakas, Inflammatory Muscle Diseases. Longo DL, éditeur, N Engl J Med, vol.372, issue.18, pp.1734-1781, 2015.

L. Iaccarino, A. Ghirardello, S. Bettio, M. Zen, M. Gatto et al., The clinical features, diagnosis and classification of dermatomyositis, Journal of Autoimmunity. févr, pp.122-129, 2014.

L. G. Rider and F. W. Miller, Laboratory Evaluation of the Inflammatory Myopathies, CLIN DIAGN LAB IMMUNOL, vol.2, p.9, 1995.

J. Van-de-vlekkert, M. Maas, J. E. Hoogendijk, D. Visser, M. et al., Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy: Combining MRI and Muscle Biopsy in IIM, Muscle Nerve. févr, vol.51, issue.2, pp.253-261, 2015.

L. Yao, A. L. Yip, J. A. Shrader, S. Mesdaghinia, R. Volochayev et al., Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies, Rheumatology. 27 sept, p.344, 2015.

C. Cai, D. C. Anthony, and P. Pytel, A pattern-based approach to the interpretation of skeletal muscle biopsies, Modern Pathology. avr, vol.32, issue.4, pp.462-83, 2019.

A. Selva-o'callaghan, I. Pinal-fernandez, E. Trallero-araguas, J. C. Milisenda, J. M. Grau-junyent et al., Classification and management of adult inflammatory myopathies, The Lancet Neurology, vol.17, issue.9, pp.816-828, 2018.

C. V. Oddis and R. Aggarwal, Treatment in myositis, Nature Reviews Rheumatology. mai, vol.14, issue.5, pp.279-89, 2018.

G. C. Dobloug, J. Svensson, I. E. Lundberg, and M. Holmqvist, Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study, Ann Rheum Dis. janv, vol.77, issue.1, pp.40-47, 2018.

G. C. Dobloug, T. Garen, C. Brunborg, J. T. Gran, and Ø. Molberg, Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort, Seminars in Arthritis and Rheumatism. déc, vol.45, issue.3, pp.301-309, 2015.

A. Aussy, O. Boyer, and N. Cordel, Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on, Autoimmunity and Cancer. Front Immunol. 21 août, vol.8, p.992, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02377507

X. Lu, H. Yang, X. Shu, F. Chen, Y. Zhang et al., Factors Predicting Malignancy in Patients with Polymyositis and Dermatomyostis: A Systematic Review and Meta-Analysis

M. Kuwana, PLoS ONE. 8 avr, vol.9, issue.4, p.94128, 2014.

R. Neri, B. Simone, V. Iacopetti, G. Iacopetti, P. Pepe et al., Cancer-associated myositis: a 35-year retrospective study of a monocentric cohort, Rheumatol Int. avr, vol.34, issue.4, pp.565-574, 2014.

J. Wang, G. Guo, G. Chen, B. Wu, and L. Lu, Metaanalysis of the association of dermatomyositis and polymyositis with cancer, British Journal of Dermatology, vol.10, 2013.

A. Oldroyd, J. C. Sergeant, P. New, N. J. Mchugh, Z. Betteridge et al., The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis, Rheumatology. 1 avr, vol.58, issue.4, pp.650-655, 2019.

S. L. Tansley, S. Simou, G. Shaddick, Z. E. Betteridge, B. Almeida et al., Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort, Journal of Autoimmunity, vol.84, pp.55-64, 2017.

I. Marie, L. Guillevin, J. Menard, P. Y. Hatron, C. P. Amoura et al., Hematological malignancy associated with polymyositis and dermatomyositis, Autoimmunity Reviews. juill, vol.11, issue.9, pp.615-635, 2012.

Y. Liu, L. Xu, H. Wu, N. Zhao, Y. Tang et al., Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China, Oncol Lett

D. Sur,

C. L. Hill, Y. Zhang, B. Sigurgeirsson, E. Pukkala, L. Mellemkjaer et al., Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study, The Lancet, vol.357, issue.9250, pp.96-100, 2001.

C. Lin, Z. Ying, and C. Sijing, Spontaneous resolution of dermatomyositis associated with fallopian-tube carcinoma following staging surgery: A case report, Medicine. mars, vol.98, issue.10, p.14530, 2019.

E. C. Carruthers, H. K. Choi, E. C. Sayre, and J. A. Aviña-zubieta, Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study, Ann Rheum Dis. janv, vol.75, issue.1, pp.110-116, 2016.

A. Redondo-benito, A. Curran, A. Villar-gomez, E. Trallero-araguas, A. Fernández-codina et al., Opportunistic infections in patients with idiopathic inflammatory myopathies, Int J Rheum Dis. févr, vol.21, issue.2, pp.487-96, 2018.

I. Chen, W. Tsai, Y. Wu, S. Luo, H. Ho et al., Infections in polymyositis and dermatomyositis: analysis of 192 cases, Rheumatology. 1 déc, vol.49, issue.12, pp.2429-2466, 2010.

C. Lee, C. Muo, J. Liang, F. Sung, C. Hsu et al., Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score, Endocrine. avr, vol.52, issue.1, pp.86-92, 2016.

I. E. Lundberg, M. De-visser, and V. P. Werth, Classification of myositis, Nature Reviews Rheumatology. mai, vol.14, issue.5, pp.269-78, 2018.

V. Leclair and I. E. Lundberg, New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter, Current Rheumatology Reports [Internet]. avr, vol.20, issue.4, 2018.

Z. Betteridge and N. Mchugh, Myositis-specific autoantibodies: an important tool to support diagnosis of myositis, Journal of Internal Medicine. juill, vol.280, issue.1, pp.8-23, 2016.

B. Stuhlmüller, U. Schneider, J. González-gonzález, and E. Feist, Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies, Front Neurol. 8 mai, vol.10, p.438, 2019.

I. N. Targoff and M. Reichlin, The association between Mi-2 antibodies and dermatomyositis, Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, vol.28, issue.7, pp.796-803, 1985.

N. J. Mchugh and S. L. Tansley, Autoantibodies in myositis, Nature Reviews Rheumatology. mai, vol.14, issue.5, pp.290-302, 2018.

C. Fernandez, N. Bardin, D. Paula, A. M. Salort-campana, E. Benyamine et al., Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies: Study of 178 Cases and Guidelines for Diagnosis, Medicine. janv, vol.92, issue.1, pp.15-24, 2013.

C. Johnson, I. Pinal-fernandez, R. Parikh, J. Paik, J. Albayda et al., Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease. Lung, vol.194, pp.733-740, 2016.

D. F. Fiorentino, L. S. Chung, L. Christopher-stine, L. Zaba, S. Li et al., Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1?: Antibodies to NXP-2 and TIF-1? in Cancer-Associated Dermatomyositis. Arthritis & Rheumatism, Based on Clinical Manifestations and Myositis-Specific Autoantibodies, vol.65, p.1528, 2013.

T. P. O'hanlon, L. G. Rider, G. Mamyrova, I. N. Targoff, F. C. Arnett et al., HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies, Arthritis Rheum, vol.54, issue.11, pp.3670-81, 2006.

I. Pinal-fernandez, B. Ferrer-fabregas, E. Trallero-araguas, E. Balada, M. A. Martínez et al., Tumour TIF1 mutations and loss of heterozygosity related to cancerassociated myositis, Rheumatology. 1 févr, vol.57, issue.2, pp.388-96, 2018.

C. G. Joseph, E. Darrah, A. A. Shah, A. D. Skora, L. A. Casciola-rosen et al., Association of the Autoimmune Disease Scleroderma with an Immunologic Response to, Cancer. Science. 10 janv, vol.343, issue.6167, pp.152-159, 2014.

R. Aggarwal, C. V. Oddis, D. Goudeau, D. Koontz, Z. Qi et al., Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab, Rheumatology. 1 juin, vol.55, issue.6, pp.991-1000, 2016.

S. Sakamoto, M. Okamoto, S. Kaieda, K. Fujimoto, S. Nagata et al., Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Respiratory Investigation, vol.56, pp.464-72, 2018.

K. B. Stone, C. V. Oddis, N. Fertig, Y. Katsumata, M. Lucas et al., Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy, Arthritis Rheum. sept, vol.56, issue.9, pp.3125-3156, 2007.

J. L. Werner, L. Christopher-stine, S. R. Ghazarian, K. S. Pak, J. E. Kus et al., Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy, Arthritis & Rheumatism. déc, vol.64, issue.12, pp.4087-93, 2012.

O. Benveniste, L. Drouot, F. Jouen, J. Charuel, C. Bloch-queyrat et al., Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy, Arthritis & Rheumatism. juill, vol.63, issue.7, pp.1961-71, 2011.

C. Bergua, H. Chiavelli, Y. Allenbach, L. Arouche-delaperche, C. Arnoult et al., In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy, Ann Rheum Dis. janv, vol.78, issue.1, pp.131-140, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02366089

S. Morikawa, T. Murakami, H. Yamazaki, A. Izumi, Y. Saito et al., Analysis of the Global RNA Expression Profiles of Skeletal Muscle Cells Treated with Statins, JAT, vol.12, issue.3, pp.121-152, 2005.

L. A. Love, C. R. Weinberg, D. R. Mcconnaughey, C. V. Oddis, T. A. Medsger et al., Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women, Arthritis Rheum. août, vol.60, issue.8, pp.2499-504, 2009.

I. Cavazzana, M. Fredi, A. Ceribelli, C. Mordenti, F. Ferrari et al., Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera, Journal of Immunological Methods. juin, vol.433, pp.1-5, 2016.

M. Mahler, Z. Betteridge, C. Bentow, M. Richards, A. Seaman et al., Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies. Front Immunol, vol.10, p.848, 2019.

M. Mahler, J. Vulsteke, X. Bossuyt, E. De-langhe, and M. Satoh, Standardisation of myositisspecific antibodies: where are we today?, Ann Rheum Dis. 3 août, 2019.

M. Satoh, S. Tanaka, A. Ceribelli, S. J. Calise, and E. Chan, A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy, Clinical Reviews in Allergy & Immunology. févr, vol.52, issue.1, pp.1-19, 2017.

R. Aggarwal, N. Dhillon, N. Fertig, D. Koontz, Z. Qi et al., A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome, J Rheumatol. févr, vol.44, issue.2, pp.223-232, 2017.

J. Vulsteke, D. Langhe, E. Claeys, K. G. Dillaerts, D. Poesen et al., Detection of myositis-specific antibodies, Ann Rheum Dis. janv, vol.78, issue.1, pp.7-7, 2019.

A. Tjärnlund, J. Rönnelid, M. Bottai, and I. E. Lundberg, Response to: 'Detection of myositisspecific antibodies' by Vulsteke et al, Ann Rheum Dis. janv, vol.78, issue.1, pp.8-8, 2019.

R. Mierau, Less specific myositis autoantibodies?, Annals of the Rheumatic Diseases. 1 août, vol.60, issue.8, pp.810-810, 2001.

J. Lega, N. Fabien, Q. Reynaud, I. Durieu, S. Durupt et al., The clinical phenotype associated with myositis-specific and associated autoantibodies: A metaanalysis revisiting the so-called antisynthetase syndrome, Autoimmunity Reviews. sept, vol.13, issue.9, pp.883-91, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02046821

M. Segelmark and T. Hellmark, Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies, Nephrology Dialysis Transplantation

D. Sur,

S. P. Mcadoo, A. Tanna, Z. Hru?ková, L. Holm, M. Weiner et al., Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients, Kidney International. sept, vol.92, issue.3, pp.693-702, 2017.

C. Neville, J. Rauch, J. Kassis, C. E. Joseph, L. et al., Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies, Thromb Haemost, vol.90, issue.07, pp.108-123, 2003.

R. Forastiero and M. Martinuzzo, The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome. Expert Review of Clinical Immunology, vol.11, pp.1255-63, 2015.

X. Wu, Y. Lun, H. Jiang, Q. Gang, S. Xin et al., Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroidstimulating hormone level and advanced tumor stage of papillary thyroid cancer, Endocrine. août, vol.46, issue.3, pp.554-60, 2014.

T. Dick, Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis, Annals of the Rheumatic Diseases. 1 févr, vol.61, issue.2, pp.121-128, 2002.

A. Ghirardello and A. Doria, New insights in myositis-specific autoantibodies: Current Opinion in Rheumatology, vol.30, pp.614-636, 2018.

I. Marie, P. Y. Hatron, D. S. , C. P. Mouthon, L. Menard et al., Short-Term and Long-Term Outcome of Anti-Jo1-Positive Patients with Anti-Ro52 Antibody, Seminars in Arthritis and Rheumatism. juin, vol.41, issue.6, pp.890-899, 2012.

C. Gelpi, E. Kanterewicz, J. Gratacos, I. N. Targoff, and J. L. Rodriguez-sanchez, Coexistence of two antisynthetases in a patient with the antisynthetase syndrome, Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, vol.39, issue.4, pp.692-697, 1996.

K. Sugie, Y. Tonomura, and S. Ueno, Characterization of Dermatomyositis with Coexistence of Anti-Jo-1 and Anti-SRP Antibodies, Intern Med, vol.51, issue.7, pp.799-802, 2012.

M. Vincze, P. A. Molnár, J. Tumpek, L. Sz?ll?si, Á. Gyetvai et al., An unusual association: anti-Jo1 and anti-SRP antibodies in the serum of a patient with polymyositis, Clin Rheumatol. juill, vol.29, issue.7, pp.811-815, 2010.

A. Nakajima, K. Yoshino, M. Soejima, Y. Kawaguchi, T. Satoh et al., High Frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis, Rheumatology International. juill, vol.32, issue.7, pp.2057-61, 2012.

Y. Takeuchi, M. Hashimoto, R. Nakashima, M. Tanaka, N. Kuramoto et al., Anti-EJ, anti-MDA5 double-positive chronic clinically amyopathic dermatomyositis: a case report, Disponible sur, vol.2, 2018.

Z. Betteridge, S. Tansley, G. Shaddick, H. Chinoy, R. G. Cooper et al., Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients, Journal of Autoimmunity. juill, vol.101, pp.48-55, 2019.

M. Infantino, M. Tampoia, M. Fabris, M. G. Alessio, G. Previtali et al., Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis, Rheumatology. 1 juill, vol.58, issue.7, pp.1239-1283, 2019.

L. Huang, L. Wang, Y. Yang, H. Chen, Y. Liu et al., Coexistence of anti-HMGCR and anti-MDA5 identified by an unlabeled immunoprecipitation assay in a chinese patient cohort with myositis: Medicine, vol.97, p.13236, 2018.

M. Infantino, M. Manfredi, and N. Bizzaro, Correspondence to 'Standardisation of myositisspecific antibodies: where are we today?' by Mahler et al, Ann Rheum Dis. 6 sept, pp.2019-216217, 2019.

C. Picard, T. Vincent, J. Lega, S. Hue, F. Fortenfant et al., Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study, Immunol Res. juin, vol.64, issue.3, pp.677-86, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01821459

J. Damoiseaux, L. Andrade, O. G. Carballo, K. Conrad, P. Francescantonio et al., Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective, Ann Rheum Dis. juill, vol.78, issue.7, pp.879-89, 2019.

M. Lecouffe-desprets, C. Hémont, A. Néel, C. Toquet, A. Masseau et al., Clinical contribution of myositis-related antibodies detected by immunoblot to idiopathic inflammatory myositis: A one-year retrospective study, Autoimmunity. 17 févr, vol.51, issue.2, pp.89-95, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01881121

E. H. Kang, D. J. Go, T. Mimori, S. J. Lee, H. M. Kwon et al., Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients. Seminars in Arthritis and Rheumatism, vol.49, pp.283-290, 2019.

Y. Muro, A. Ishikawa, K. Sugiura, and M. Akiyama, Clinical features of anti-TIF1-antibodypositive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-or anti-Mi-2 autoantibodies, Rheumatology. 1 août, vol.51, issue.8, pp.1508-1521, 2012.

C. Bundell, A. Rojana-udomsart, F. Mastaglia, P. Hollingsworth, and A. Mclean-tooke, Diagnostic performance of a commercial immunoblot assay for myositis antibody testing, Pathology. juin, vol.48, issue.4, pp.363-369, 2016.

, Diagnostic différentiel des myopathies inflammatoires idiopathiques, vol.2

, Myopathies associées aux endocrinopathies (dysthyroïdie, hypercorticisme

, Myosite focale

, Myopathies toxiques : alcool ou médicament (corticoïde, colchicine, hydroxychloroquine, statine, antirétroviraux

, Myopathies à bâtonnet acquises (VIH, gammapathie monoclonale)

, Myosite de dénervation (radiculopathie, maladie du motoneurone)

, Traumatisme, vol.56

, Annexe 3 : Répartition des spécialités dans les prescriptions des DOT-myosites

, Répartition des patients avec un DOT positif, négatif ou douteux selon le sexe Annexe 5 : Age des patients selon l, Annexe, vol.4

, Annexe 6 : Répartition des sexes selon les ASM